According to a Korean stock exchange disclosure form, Samsung Bioepis and Merck & Co. have ended their agreement to develop and commercialise Lusduna Nexvue,?also known as MK-1293, a follow-on?biologic?referencing?Sanofi's diabetes therapy Lantus (insulin glargine).?The agreement had built upon an earlier deal?between the companies?to form a joint venture?to develop and market a number of biosimilar candidates. "[Merck] decided to end the product development and commercialisation after?reviewing the market environment and production costs," a Samsung Biologics official explained, noting that the company has received $155 million in compensation from Merck over its decision to end the collaboration. Merck received tentative approval of its Lusduna Nexvue?filing?from the FDA in July last year.?At the time, Merck explained that while Lusduna Nexvue had achieved all required regulatory standards for follow-on biologics, final approval was delayed?due to a patent infringement lawsuit filed by Sanofi in 2016 related to the latter's insulin glargine products Lantus and Lantus SoloSTAR.